Walter Greenblatt & Associates | Bridging the Gap Between Science & Investment
from
INCEPTION
to
EXIT
INCEPTION
WALTER GREENBLATT & ASSOC.
helps scientists raise the captial they need to create proof-of-concepts
DEVELOPMENT
WALTER GREENBLATT & ASSOC.
helps scientists bring their product to the market
GROWTH
WALTER GREENBLATT & ASSOC.
helps raise capital necessary for company to reach the next stage of development
EXIT
WALTER GREENBLATT & ASSOC.
helps biotech owners plan exit strategies that yield “Maximum Value”
Bridging the Gap
Between Science & Investment
Investment Banking Services
Investment Banking
Capital Raising
Strategic Planning
M&A Advisory
Acquisitions and In-Licensing
M&A Advisory—
Sale and Product Outlicensing
How We Build Companies
Inception to Exit
Case Studies
About Us
About Us
Our Team
Our Clients
Representative Transactions
News
Contact Us
Representative Transactions
News
March 2013
Callidus Biopharma
receives $3.0 million from strategic investors.
Read the full press release...
January 2012
Callidus Biopharma
receives $1.6 million from Angel and strategic investors.
August 2011
Lerner Medical Devices
receives $1.0 million from Angel investors.
2009-10
Lerner Medical receives $4.5 million from Angel investors.
Dec. 2007
Lerner Medical receives $3.3 million from Angel investors.
March 2011
Core Essence Orthopaedics
receives $5.2 million Series B from institutional VC investors.
October 2010
Core Essence Orthopaedics
receives a $2.9 million Series A from Angel investors.
March 2010
Hygeia Therapeutics
receives $2.0 million from Angel Investors.
June 2008
MedAvante
receives $20 million from institutional VC investors.
Sept. 2007
MedAvante receives $6.7 million from Angel investors.
July 2011
Shire Pharmaceuticals purchases Advanced BioHealing for $750 million in cash.
November 2009
Lerner Medical Devices receives 510(k) clearance from the FDA for Levia®.
June 2008
MedAvante closes on $20 million Institutional round led by Goldman Sachs and Trevi Health Ventures; Walter Greenblatt & Associates, exclusive financial advisor to MedAvante.
August 2007
WuXi PharmaTech (NYSE: WX), IPOs on the New York Stock Exchange with a $1 billion market cap.
More
